Tenax Therapeutics Inc (NASDAQ:TENX) Stock Is Shorted Less

July 14, 2018 - By Tamara Reed

The stock of Tenax Therapeutics Inc (NASDAQ:TENX) registered a decrease of 4.06% in short interest. TENX’s total short interest was 158,400 shares in July as published by FINRA. Its down 4.06% from 165,100 shares, reported previously. With 52,700 shares average volume, it will take short sellers 3 days to cover their TENX’s short positions. The short interest to Tenax Therapeutics Inc’s float is 0.73%.

The stock decreased 2.67% or $0.18 during the last trading session, reaching $6.55. About 3,144 shares traded. Tenax Therapeutics, Inc. (NASDAQ:TENX) has declined 40.67% since July 14, 2017 and is downtrending. It has underperformed by 53.24% the S&P500.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. The company has market cap of $9.52 million. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. It currently has negative earnings. The firm was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.